AP
ABVX

Andera Partners’s Abivax ABVX Stock Holding History

Andera Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.7M Hold
78,125
– – 4.92% 6
2025
Q4 		$10.5M Buy
+78,125
New +$8.52M 5.97% 4

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Andera Partners's ABVX Position: Q1 2026 in Review

Andera Partners held its Abivax (ABVX) position steady in Q1 2026 at 78,125 shares worth $8.7M. The position accounts for 4.92% of the portfolio, ranked #6.

Andera Partners first reported a position in ABVX in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.5M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Andera Partners held 78,125 shares of Abivax worth $8.7M as of Q1 2026.
  • Andera Partners left its Abivax share count unchanged in Q1 2026.
  • Abivax made up 4.92% of Andera Partners's portfolio in Q1 2026, its #6 holding.
  • Andera Partners first reported a position in Abivax in Q4 2025 and has held it in 2 quarters since.
  • Andera Partners's Abivax position peaked at $10.5M in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Andera Partners's 13F filing for Q1 2026, filed 11 May 2026.